With growing interest in natural supplements for weight loss, many are curious about the potential link between Estrovera and weight loss. Estrovera, derived from Siberian rhubarb (ERr 731), primarily helps alleviate menopausal symptoms such as hot flashes, mood swings, and sleep disturbances. While there is no direct evidence linking Estrovera specifically to weight loss, its indirect effects can contribute to better weight management.
Understanding Estrovera
Estrovera is a natural supplement derived from Siberian rhubarb (ERr 731). Its key ingredient, ERr731, has been used safely and effectively for over 20 years and is supported by clinical studies. It offers several benefits that can significantly enhance the quality of life for menopausal women. The extract is derived from the plant’s roots and is indicated for menopausal relief. A standardized version of the extract, ERr 731, was commercially registered in Germany in July 1993 as Phytoestrol N. ERr 731 was also launched in Germany in 2011 with the name femi-loges. It was introduced as the dietary supplement Estrovera in 2009 in the United States, in 2012 in Canada, and in 2011 in South Africa.
Benefits of Estrovera
Estrovera provides relief for multiple menopausal symptoms, including hot flashes, sleep disturbances, mood swings, irritability, anxiety, and sexual problems. One of the primary benefits of Estrovera is its ability to reduce hot flashes, a common and often disruptive symptom of menopause. Another major advantage is the improvement in mood and emotional well-being. Menopause can bring about mood swings and feelings of irritability or depression. Better sleep is another critical benefit, as the reduction in menopausal symptoms such as night sweats and anxiety leads to more restful and uninterrupted sleep.
The Indirect Link to Weight Loss
There is limited direct evidence linking Estrovera to weight loss. Most benefits are indirect, such as improved sleep and reduced stress, which can help manage weight.
- Hormone Balance: Estrovera’s role in balancing hormones, particularly estrogen, can positively impact metabolism. During menopause, fluctuating hormone levels can lead to weight gain and a slower metabolism.
- Improved Sleep: Better sleep is a significant factor in weight management. Menopausal symptoms often disrupt sleep, leading to fatigue and poor dietary choices. By alleviating menopause symptoms like hot flashes and mood swings, Estrovera can improve sleep quality.
- Stress Reduction: Stress and mood swings during menopause can lead to emotional eating and weight gain. By alleviating these symptoms, Estrovera helps reduce stress levels, potentially decreasing the likelihood of stress-related eating.
Anecdotal evidence from users suggests that the relief of menopausal symptoms provided by Estrovera can make it easier to follow a balanced diet and exercise regimen, thus supporting weight management efforts.
Read also: Weight Loss Guide Andalusia, AL
Estroven® Menopause Relief Weight Management
Estroven® Menopause Relief Weight Management can help manage the symptoms and changes your body goes through during this time. Estroven® Menopause Relief Weight Management contains a proprietary ingredient, CQR-300®, which helps you manage your weight by addressing serotonin levels. Research shows that serotonin, a key compound in our bodies, declines with age, especially following menopause and its associated declining estrogen levels. Serotonin is a very important compound assisting in appetite regulation. CQR-300® is the brand name for a proprietary standardized extract of Cissus quadrangularis, a plant native to West Africa, Southeast Asia and India.
Managing weight is challenging for many premenopausal and menopausal women as merely eating healthy isn’t enough to help these women address their rapidly changing bodies. Estroven® Menopause Relief Weight Management is different from other non-menopausal weight management products because it is specifically formulated to address the effects associated with the decline of estrogen. It is not a weight loss and/or diet product.
Safety and Side Effects
When considering the use of Estrovera, it’s important to be aware of its safety and potential side effects. Common side effects include digestive issues such as nausea and stomach discomfort, and allergic reactions like skin rashes. Postmarketing surveillance data for a commercially available extract of Rheum rhaponticum (ERr 731) have not been published since the beginning of the reporting in 1993 in Germany about adverse events (AEs) that were believed to be associated with it.
From 1993 to June 2014, approximately 140 million daily doses of the extract were placed on the German market, and 124 AE reports were recorded. The most common of those AEs were hypersensitivity, with 74 reactions, and gastrointestinal symptoms, with 47 reactions. From January 2009 to June 2014, approximately 13 million tablets of the supplement were sold in North America, and 79 complaints from consumers associated with a physical response to it had been recorded. The main complaints were gastrointestinal symptoms, with 23 cases, and failure to work as suggested, with 22 cases.
Estrovera has been shown to have a favorable long-term safety profile, particularly in relieving menopausal symptoms. However, it’s crucial to consult with a healthcare provider before starting Estrovera, especially if you have existing health conditions or are taking other medications.
Read also: Beef jerky: A high-protein option for shedding pounds?
Alternative Approaches to Weight Loss During Menopause
While Estrovera is popular for managing menopause symptoms, other natural supplements can also support weight loss. Berberine is notable for its effects on metabolic health, helping manage blood sugar levels and promoting fat loss. In addition to supplements, lifestyle changes are crucial for weight loss during menopause.
Lifestyle Changes
A balanced diet rich in whole foods, lean proteins, healthy fats, and fiber supports overall health and weight management. Stress management techniques such as yoga, meditation, and deep breathing exercises can also be beneficial.
Other Natural Supplements
Alternatives to Estrovera include other natural supplements like black cohosh and red clover.
Postmarketing Surveillance Data
Postmarketing surveillance data for a commercially available extract of Rheum rhaponticum (ERr 731) have not been published since the beginning of the reporting in 1993 in Germany about adverse events (AEs) that were believed to be associated with it. The extract is derived from the plant’s roots and is indicated for menopausal relief.
From 1993 to June 2014, approximately 140 million daily doses of the extract were placed on the German market, and 124 AE reports were recorded. The most common of those AEs were hypersensitivity, with 74 reactions, and gastrointestinal symptoms, with 47 reactions.
Read also: Inspiring Health Transformation
From January 2009 to June 2014, approximately 13 million tablets of the supplement were sold in North America, and 79 complaints from consumers associated with a physical response to it had been recorded. The main complaints were gastrointestinal symptoms, with 23 cases, and failure to work as suggested, with 22 cases.
Adverse Event Reporting
In both the United States and Canada in North America, and in South Africa, health authorities do not require submission of AE reports by health care professionals and consumers for events that are suspected to be associated with dietary supplements. However, after health care professionals or consumers have reported suspected AEs to a product’s manufacturer, that company is required to send the report to regulatory authorities.
Consumers’ complaints from North America and South Africa that have been related to the extract sold as Estrovera have been actively recorded by its distributor since the product’s launch.
Analysis of Adverse Events
The PSURs for Phytoestrol N and other related products-Phyto-Strol, Phyto-Strol Loges, and Phyto-Strol compact-were obtained from one MAH, Chemisch-Pharmazeutische Fabrik Göppingen, Carl Müller, Apotheker, GmbH & Co. KG (Göppingen, Germany), and the information on the suspected AEs was analyzed. A second MAH, Dr. Loges + Co. GmbH (Winsen [Luhe], Germany), had also authorized the extract and launched a product in January 2011 with the name femi-loges.
Records for consumers’ complaints related to the extract in North America and South Africa were captured by the distributor when consumers directly used the toll-free product hotline or Web site or when a health care practitioner who had received a user’s complaint informed them.
Classification of Adverse Reactions
The physical reactions were classified as expected (i.e., they were mentioned on the Summary of Product Characteristics [SmPC] in the product’s package) or unexpected (i.e., they not mentioned in the SmPC). Further, an event more specific or more severe than described in the SmPC was considered “unexpected.”
Seriousness of Reactions
The decision whether a reaction was serious or not was based on the criteria for “seriousness” defined in the ICH guideline E2B (R3). A reaction is considered as serious when the following criteria apply: The reaction (1) results in death, (2) is life-threatening, (3) requires inpatient hospitalization or prolongation of existing hospitalization, (4) results in persistent or significant disability/incapacity, (5) is a congenital anomaly/birth defect, and (6) other medically important condition.
Overall Safety Profile
Approximately 140 million daily doses of products using the extract of R rhaponticum, ERr 731, were placed on the German market from July 1993 to June 2014, and within that period, 124 predominantly nonserious AE reports were documented. Approximately 13 million tablets of supplements using the extract had been sold in North America and South Africa from the product’s launch up to June 2014, and 79 complaints from consumers, including 1 serious AE, had been recorded. Thus, the incidence of AEs can be considered to be very low.
Limitations of Data
The limitation of underreporting cannot be overlooked and, thus, data should be interpreted with caution. Missing information on treatment duration in many AE reports also precluded the assessment of the long-term safety of the extract. Often the symptoms that are reported as AEs were ones that are typical for menopause (eg, headache, sleep disturbance, or breast pain) or had nothing to do with either the extract or menopause.